These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation. Solga AC; Toonen JA; Pan Y; Cimino PJ; Ma Y; Castillon GA; Gianino SM; Ellisman MH; Lee DY; Gutmann DH Oncotarget; 2017 Jul; 8(29):47206-47215. PubMed ID: 28525381 [TBL] [Abstract][Full Text] [Related]
6. Neurofibromatosis type 1-associated optic pathway gliomas: pathogenesis and emerging treatments. Amato A; Imbimbo BP; Falsini B Eur Rev Med Pharmacol Sci; 2023 Jun; 27(12):5636-5653. PubMed ID: 37401302 [TBL] [Abstract][Full Text] [Related]
7. NG2-cells are not the cell of origin for murine neurofibromatosis-1 (Nf1) optic glioma. Solga AC; Gianino SM; Gutmann DH Oncogene; 2014 Jan; 33(3):289-99. PubMed ID: 23318450 [TBL] [Abstract][Full Text] [Related]
8. A molecular analysis of individuals with neurofibromatosis type 1 (NF1) and optic pathway gliomas (OPGs), and an assessment of genotype-phenotype correlations. Sharif S; Upadhyaya M; Ferner R; Majounie E; Shenton A; Baser M; Thakker N; Evans DG J Med Genet; 2011 Apr; 48(4):256-60. PubMed ID: 21278392 [TBL] [Abstract][Full Text] [Related]
9. Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma. Venkatesh HS; Tam LT; Woo PJ; Lennon J; Nagaraja S; Gillespie SM; Ni J; Duveau DY; Morris PJ; Zhao JJ; Thomas CJ; Monje M Nature; 2017 Sep; 549(7673):533-537. PubMed ID: 28959975 [TBL] [Abstract][Full Text] [Related]
10. An Overview of Optic Pathway Glioma With Neurofibromatosis Type 1: Pathogenesis, Risk Factors, and Therapeutic Strategies. Chen Y; Yu J; Ge S; Jia R; Song X; Wang Y; Fan X Invest Ophthalmol Vis Sci; 2024 Jun; 65(6):8. PubMed ID: 38837168 [TBL] [Abstract][Full Text] [Related]